News
-
23.06.2009
Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations - -
18.06.2009
Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development for treatment of solid tumours - A novel drug with potential to block cancer cell proliferation
| Licensing-out |
|
We would typically partner our products at human proof of concept stage or later on. It is crucial that our products are commercialised by the appropriate commercial partner for the best possible fit. We make sure that the inventor and the marketing company are fairly remunerated for their work. Financial scenarios are analysed, commercial terms are negotiated, the future envisioned and discussed, legal contracts put in place and business alliance management implemented to ensure the product is optimally exploited. |



